In this review, we aim to characterize the types of HER2 alterations in NSCLC, discuss the diagnostic challenges in identifying activating HER2 alterations, and review the application of HER2 targeted agents in patient care by discussing clinical trial data on HER2 agents. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.